Review
Nature Reviews Drug Discovery 2, 717-726 (September 2003) | doi:10.1038/nrd1177
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Sanjay Kumar1, Jeffrey Boehm1 & John C. Lee1 About the authors
Abstract
The p38 MAP kinases are a family of serine/threonine protein kinases that play important roles in cellular responses to external stress signals. Since their identification about 10 years ago, much has been learned of the activation and regulation of the p38 MAP kinase pathways. Inhibitors of two members of the p38 family have been shown to have anti-inflammatory effects in preclinical disease models, primarily through the inhibition of the expression of inflammatory mediators. Several promising compounds have also progressed to clinical trials. In this review, we provide an overview of the role of p38 MAP kinases in stress-activated pathways and the progress towards clinical development of p38 MAP kinase inhibitors in the treatment of inflammatory diseases.
- View At a Glance
Author affiliations
- GlaxoSmithKline Pharmaceuticals Research & Development, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, USA.
Correspondence to: John C. Lee1 Email: john.c.lee@gsk.com
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated NEWS AND VIEWS RESEARCH |
MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
